GlucoTrack, Inc. Common Stock

E.F. Hutton & Co. served as exclusive financial advisor and placement agent for a strategic business combination between Glucotrack, Inc. and Lōkahi Therapeutics, along with a $5.7 million convertible note financing. The transaction creates a publicly traded healthcare platform combining Lōkahi's AI-driven asset sourcing capabilities with Gluco...

Glucotrack, Inc. (NASDAQ: GCTK) completed a strategic business combination with Lōkahi Therapeutics, creating a publicly listed platform for identifying and advancing healthcare assets. Lōkahi Therapeutics securityholders will hold approximately 90% of the combined company on a fully diluted basis. Erik Emerson was appointed CEO, while Glucotra...

Glucotrack Inc. (NASDAQ: GCTK) submitted an Investigational Device Exemption (IDE) application to the FDA for its fully implantable continuous blood glucose monitoring (CBGM) technology, targeting U.S. clinical trial launch in H2 2026. The company reported Q1 2026 net loss of $4.3 million versus $6.8 million in Q1 2025, with cash position of $3.9...

Glucotrack, Inc. (NASDAQ: GCTK) announced the submission of its Investigational Device Exemption (IDE) application to the FDA to initiate a U.S. clinical study for its fully implantable continuous blood glucose monitoring (CBGM) technology. The submission follows years of preclinical development and represents a significant milestone toward clini...

Glucotrack reported full year 2025 net loss of $19.4 million, an improvement from $22.6 million in 2024. The company completed a $4.0 million private placement, received three new USPTO patents for its implantable continuous blood glucose monitoring technology, and plans to file an Investigational Device Exemption (IDE) with the FDA in Q2 2026 to...